Mild Encephalopathy in the Newborn Treated With Darbepoetin

Key facts

Sponsor

University of New Mexico

Principal Investigator

Tara L DuPont, MD

University of Utah

Intervention

Darbepoetin Alfa(drug)

Enrollment

28 target

Eligibility

All sexes

Timeline

2017 – 2022

Study locations (1)

• University of Utah, Salt Lake City, Utah, United States

Collaborators

University of Utah

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neonatal hypoxic and ischemic brain injury

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07464938
  New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest
  Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• ENROLLING BY INVITATIONNCT07264166
  Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE)
  Healing Hope International
• ENROLLING BY INVITATIONPHASE1NCT06429007
  A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury
  Boston Children's Hospital
• RECRUITINGNANCT06762795
  The HIEnome Study: Genome Sequencing for Perinatal HIE
  Baylor College of Medicine
• RECRUITINGNCT07136636
  Speech of Kids After Neonatal Encephalopathy
  Semmelweis University
• RECRUITINGEARLY PHASE1NCT06746532
  Intranasal Breast Milk Therapy in HIE
  Semmelweis University
• RECRUITINGEARLY PHASE1NCT06747260
  Feasibility and Safety of Intranasally Administered Breast Milk in HIE
  Semmelweis University
• RECRUITINGNANCT06563687
  Continuous Glucose Monitoring in HIE
  University of Campania Luigi Vanvitelli

See all trials for Neonatal hypoxic and ischemic brain injury →